Risk factors
Crescent Biopharma (CBIO) risk factors
Item 1A of every Crescent Biopharma, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors59 risks53 new50 dropped6 reworded
Post-merger Crescent Biopharma is heavily focused on advancing its lead bi-specific antibody CR-001 and ADC programs CR-002 and CR-003. Clinical development and partner dependencies on Paragon Therapeutics dominate the updated risk profile.
Filed Feb 26, 2026 - FY2024 10-K risk factors56 risks
Crescent Biopharma faces critical risks regarding its pending merger with GlycoMimetics and a concurrent $200.0 million private placement.
Filed Feb 13, 2025